Potential Protective Effect of a Formula Supplemented With Fermented Matrices on the Risk of Developing Neonatal Sepsis

Neonatal Sepsis Clinical Trial

Official title:

The Potential Protective Effect of a Formula Supplemented With Fermented Matrices on the Risk of Developing Neonatal Sepsis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04742582
• Other study ID #: CO-2016-02365100
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2021
• Est. completion date: February 1, 2024

Study information

• Verified date: June 2022
• Source: Heinz Italia SpA
• Contact: Fabio Mosca
• Phone: 0255032907
• Email: fabio.mosca[@]mangiagalli.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo controlled trial, with parallel groups and reference group. The aim of the study was to evaluate the hypothesis that an immunonutritional strategy, based on use of Lactobacillus paracasei CBA L74-fermented formula, prevents or limits the development of late-onset-sepsis in preterm infants.

Description:

15-20% of infant born weighing less than 1500 grams develop late-onset-sepsis. The prevention of sepsis is based on hygiene measures, on the prudent use of invasive procedures, on drug management and on early diagnosis. However, no intervention is fully effective in reducing the burden of the disease, prolonged hospitalizations in neonatal intensive care units, high costs or delayed neurodevelopmental impairment. The immunonutrition is defined as the potential to modulate the activity of the immune system throught use of specific nutrients. Many immunonutritional approaches in pediatric age act in part with a modulation of the microbiota. Functional foods derived from fermentation with probiotic strains can be used and their activity is considered specific for each strain and dose dependent. A new functional food derived from fermentation of cow's milk with Lactobacillus paracasei CBA L74 has recently been de-veloped. The fermentation was started in the presence of 106 bacteria, reaching 5.9 X 109 colony-forming units/g after a 15-h incubation at 37 C°. After heating at 85 C° for 20 s in order to inactivate the live bacteria, the formula was spray-dried. Thus, the final fermented milk powder contained only bacterial bodies and fermentation products and no living microorganisms. Lactobacillus paracasei CBA L74 was registered in the Belgian Collection BCCM/LMG and was included in the EFSA list be-tween the "Qualified Presumption of Safety microorganisms". Pre-clinical studies showed anti-infective and anti-inflammatory properties of this new fermented food. More recently, a similar effect for the L. paracasei supernatant was noted after 24 and 6 h before the LPS treatment. The supernatant protects against the release of inflammatory mediators IFN-ɣ and IL-12p40 and increases the anti-inflammatory cytokine IL-10. In a randomized controlled clinical trial, the daily supplementation of this fermented food was shown to protect children from infectious diseases and induces immunoregulatory effects. These clinical results are supported by the significant inverse correlation between the concentrations of alpha-defensins, betadefensins, cathelecidins and the secretory levels of IgA with the number of infectious diseases. In another clinical trial it was shown that a daily supplementation of this new fermented food in healthy full-term infants can stimulate the production of innate and acquired immune peptides. Finally, it was reported that milk fermented by L. paracasei CBA L74 stimultes the immune and non-immune defense mechanisms against sepsis, through a direct interaction with human enterocytes. Although currently available data suggest a positive impact on morbidity, mortality and costs related to neonatal sepsis, there is little knowledge on the use of this fermented functional food in neonatal age. In particular, there are no studies on the effects of this immunonutritional approach on pre-term infants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 876
• Est. completion date: February 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 72 Hours

Eligibility

Inclusion Criteria:

• Newborns weighing less than 1500 grams
• Gestational age <32 weeks
• Artificial feeding or Human milk not available < 30%

Exclusion Criteria:

• Voluntary interruption;
• Suspension decided by PI or PDF
• Adverse events
• Gastrointestinal disease that prevent oral feeding
• Congenital or maternal infections
• Immunodeficiencies
• Malformations
• Syndromes
• Genetic or metabolic diseases.

Related Conditions & MeSH terms

• Neonatal Sepsis
• Sepsis
• Toxemia

Intervention

Dietary Supplement:
• Preterm Infants - fed fermented formula
Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)

Other:
• Preterm Infants - fed standard formula
Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)
• Pre-term Infants - breastfed
Breastfeeding infants - Reference group

Locations

Country	Name	City	State
Italy	Unita` di Neonatologia e Terapia Intensiva Neonatale, Clinica Mangiagalli	Milano

Sponsors (1)

Lead Sponsor	Collaborator
Heinz Italia SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monitoring of the number of confirmed episodes of late-onset-sepsis during hospitalization period and potential complications of the sepsis	Data collection concerning the appearance during hospitalization of episodes of sepsis from Gram positive, Gram negative bacteria and from fungi; the occurrence of comorbidities: necrotizing enterocolitis (NEC); bronchopulmonary dysplasia (BPD); intraventricular haemorrhage (IVH), retinopathy of prematurity (ROP), the mortality rate.	from enrollment (from 0 to 72 hours of life) to discharge (estimated average 40 weeks of corrected age)
Primary	Monitoring the number of days required to achieve complete enteral feeding, presence and duration of central vascular access	Data collection concerning the number of days required to achieve complete enteral feeding, presence and duration of central vascular access	from enrollment (from 0 to 72 hours of life) to discharge (estimated average 40 weeks of corrected age)
Primary	Monitoring the growth rate	Data collection concerning the growth rate (g/ kg/ day)	from enrollment (from 0 to 72 hours of life) to discharge (estimated average 40 weeks of corrected age)
Primary	Monitoring the length of hospital stay	Data collection concerning the lenght of the hospital stay	from enrollment (from 0 to 72 hours of life) to discharge (estimated average 40 weeks of corrected age)
Primary	Psychomotor development with the Griffiths III	Evaluation of the psychomotor development through development quotient using the Griffiths III. General quotient: A scale: learning basis; B scale: language and communication; C scale: eye-manual coordination; D scale: personal-social-emotional; E scale: gross-motor; average 100, DS 15.	at 180 days of life
Secondary	Fecal dosage of cathelicidines, alfa and beta defensins, sIgA	Dosage of biomarkers levels of innate and acquired immunity (cathelicidines, alfa and beta defensins, sIgA ) on fecal samples, using ELISA kits	at the enrollment (from 0 to 72 hours of life), at 30 days of life, and discharge or 40 weeks of correct age
Secondary	Microbiota	The V region of the 16S rRNA will be amplified using specific primers and the obtained amplicons will be used for sequencing library preparation, multiplexing and paired-end sequencing on the Illumina MiSeq platform. The alpha and beta diversity at the level of the phylum, genus and species among groups and their separation in a principal coordinate analysis will be evaluated.	at the enrollment (from 0 to 72 hours of life), at 30 days of life, and discharge or 40 weeks of correct age
Secondary	Cytokines production assessment on infants blood sample	Cytokines (IL-6, IL-12p40, TNF-a) production assessment on infants blood sample, using CBA (cytokine bead array)	at the enrollment (from 0 to 72 hours of life), at 30 days of life, and discharge or 40 weeks of correct age
Secondary	Cytokines production assessment on dendritic cells culture medium	Cytokines (IL-6, IL-12p40, TNF-a) production assessment on murine dendritic cells culture medium	at the enrollment (from 0 to 72 hours of life), at 30 days of life, and discharge or 40 weeks of correct age
Secondary	Cell surface activation markers (MHC and costimulatory molecules)	Determination of cell surface activation markers (MHC and costimulatory molecules) on dendritic cell after infant serum treatment and strong inflammatory stimulus (LPS or Salmonella typhimurium)	at the enrollment (from 0 to 72 hours of life), at 30 days of life, and discharge or 40 weeks of correct age